On January 21, 2026, the World Health Organization announced that it has extended its agreement with Novartis for another five years, covering 2026 through 2030. The goal is simple and deeply human: keep leprosy treatment available free of charge to everyone who needs it, anywhere in the world.
Leprosy is curable, but the damage can be lifelong when diagnosis and treatment come too late. WHO notes that the disease can cause progressive disabilities if untreated, and that stigma still pushes many people into isolation even after they’ve been cured. This renewed commitment matters because it helps health workers reach people earlier, start treatment sooner, and prevent avoidable harm.
WHO says the partnership has been running since 2000, providing multidrug therapy and clofazimine free of cost. The new extension also includes support for single-dose rifampicin used as post-exposure prophylaxis, which can help protect close contacts and reduce transmission.
The announcement also offers a clear snapshot of progress and the work still ahead. WHO reports that in 2024, 55 of the 188 reporting countries, areas, or territories reported zero cases, while 172,717 new cases were detected worldwide that same year. In other words, this is not a victory lap yet, but it is real momentum backed by real medicine, real logistics, and real people doing hard work in clinics and communities.
In public health, good news is often quiet and practical. This is one of those moments: a renewed supply line, a longer runway for prevention, and another stretch of time where getting treated doesn’t depend on whether someone can pay.